Inobrodib (CCS1477): first-in-class p300/CBP small molecule inhibitor drug, to treat specific cancers.
Location: United Kingdom, England, South Hams
Employees: 11-50
Total raised: $171M
Founded date: 2004
Investors 7
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | BrightEdge | brightedge... |
| 20.05.2025 | Forbion | forbion.co... |
| 14.09.2021 | Future Pla... | futureplan... |
| 17.10.2025 | Avego | avego.com |
| - | Nesta Impa... | nestainves... |
| - | BrightEdge | acsbrighte... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.05.2025 | Series C | $120M | Forbion |
| 24.07.2023 | - | $25M | Pfizer Ven... |
| 16.05.2018 | - | $26M | - |
Mentions in press and media 12
| Date | Title | Description |
| 20.05.2025 | Cellcentric: $120 Million Raised For Treating Multiple Myeloma | CellCentric, a clinical-stage biotechnology company developing inobrodib (a first in class oral cancer drug to treat specific cancers, notably multiple myeloma) announced the completion of a $120 million Series C funding round. The funding ... |
| 19.05.2025 | CellCentric Raises $120M In Series C Funding | CellCentric, a Cambridge, UK-based clinical-stage biotechnology company, raised $120M in Series C funding. The round was led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as Bri... |
| 19.05.2025 | Pfizer-backed CellCentric secures $120M for further myeloma trials | Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials. The candidate in question, an oral p300/CBP inhibitor dubbed inobrodib, is currently... |
| 19.05.2025 | Forbion co-leads $120 million investment in CellCentric to advance inobrodib for treating multiple myeloma | • Funding to support late stage development of a novel oral p300/CBP inhibitor, inobrodib for the treatment of multiple myeloma • As part of its global team expansion, the company opened a new office just outside Boston in Burlington, MA • ... |
| 03.11.2023 | CellCentric to present haem clinical data at ASH | Cambridge, UK, November 4th, 2022 – CellCentric, a privately owned, clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces that the Chief Investigator of its haematological mal... |
| 24.07.2023 | CellCentric Receives $25M Strategic Investment from Pfizer | CellCentric, a Cambridge, UK- and and Manchester, UK-based biotechnology company, received a $25M strategic investment from Pfizer. Pfizer will support the company with its own clinical development program in multiple myeloma (MM) for 2024,... |
| 16.05.2018 | CellCentric raises $26 million to take first-in-class p300/CBP inhibitor into the clinic | CellCentric raises $26 million to take first-in-class p300/CBP inhibitor into the clinic 16-05-2018 CellCentric, based at Chesterford Research Park, has raised $26 million in private financing to fund clinical testing of its first-in-class ... |
| 16.05.2018 | CellCentric raises $26 million to take first-in-class p300/CBP inhibitor into the clinic | CellCentric, based at Chesterford Research Park, has raised $26 million in private financing to fund clinical testing of its first-in-class oncology drug candidate CCS1477. The funds will be used to test the novel p300/CBP inhibitor in late... |
| 28.01.2010 | Babraham research provides insight into the reprogramming of cell fate | Babraham research provides insight into the reprogramming of cell fate 28-01-2010 A discovery by Babraham scientists brings new insight into how cells are reprogrammed and a greater understanding of how the environment, or factors like nutr... |
| 04.10.2007 | Cambridge Corporate Gateway partners strike deal | Cambridge Corporate Gateway partners strike deal 04-10-2007 Cambridge Corporate Gateway's winning formula is evident once again, as two companies which met in April this year announce a significant deal. CellCentric, the Cambridge biotechno... |
Show more